Safety and Clinical Outcomes of Pembrolizumab Standard-Interval Dosing Versus Extended-Interval Dosing in Patients with Breast Cancer

By afschroeder • November 9, 2025

LeVee A, Kordic A, Ruel N, Mortimer J, Kang I, McArthur H, Lechner MG, Tsai K. Safety and Clinical Outcomes of Pembrolizumab Standard-Interval Dosing Versus Extended-Interval Dosing in Patients with Breast Cancer. Oncologist. 2025 Nov 7:oyaf371. doi: 10.1093/oncolo/oyaf371. Epub ahead of print. PMID: 41206668.

Tags: breast cancer, Endocrinology, extended-interval dosing, Hematology/Oncology, immune-related adverse events, immunotherapy, pembrolizumab, Publications

The ULK1-NCOA3 axis restrains de novo lipogenesis and prevents diet-induced steatohepatitis and fibrosis in mice

Koo YD, Castillo RT, Sukumaran Nair A, Garneau M, Gochee C, Campbell ZV, Vakil TS, Ha J, Marti A, Soto J, Das D, Martinez-Lopez N,[...]

Omitting Radioactive Iodine after Therapeutic Lateral Neck Dissection May Be the Next Step in De-Escalating Initial Treatment of Papillary Thyroid Cancer

Yeh MW. Omitting Radioactive Iodine after Therapeutic Lateral Neck Dissection May Be the Next Step in De-Escalating Initial Treatment of Papillary Thyroid Cancer. Thyroid. 2026[...]

Knowledge of Interpreter Rights and Medication Delays in Diabetes Care

Linares MA, Everett EM, Rodriguez JA, Casillas A, Brown A. Knowledge of Interpreter Rights and Medication Delays in Diabetes Care. J Immigr Minor Health. 2026[...]